FDA Center for Drug Evaluation & Research Issues Warning Letter to Intas Pharmaceuticals
April 29, 2026
April 29, 2026
WASHINGTON, April 29 -- The U.S. Department of Health and Human Services Food and Drug Administration issued the following warning letter to Intas Pharmaceuticals Limited from its Center for Drug Evaluation and Research:
* * *
Recipient: Mr. Kirti Maheshwari, Chief Operating Officer, Intas Pharmaceuticals Limited, Plot No. 255, Magnet Corporate Park, Nr. Sola Bridge, S. G. Highway, Thaltej, Ahmedabad, India
Issuing Office: Center for Drug Evaluation and Res . . .
* * *
Recipient: Mr. Kirti Maheshwari, Chief Operating Officer, Intas Pharmaceuticals Limited, Plot No. 255, Magnet Corporate Park, Nr. Sola Bridge, S. G. Highway, Thaltej, Ahmedabad, India
Issuing Office: Center for Drug Evaluation and Res . . .